Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL.
暂无分享,去创建一个
L. Sehn | M. Oestergaard | Jie Jin | M. Martelli | E. Szafer-Glusman | E. Punnoose | M. Trněný | F. Cavallo | C. Bolen | U. Vitolo | F. Zaja | T. Nielsen | D. Stewart | I. Bence-Bruckler | G. Sellam | G. Fingerle-Rowson | F. Mattiello | Qingyuan Zhang | M. Klanova | I. Bence‐Bruckler
[1] D. Dunson,et al. Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma , 2017, Cell.
[2] J. Burke,et al. Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M. Oestergaard,et al. PROGNOSTIC IMPACT OF BCL2 AND MYC EXPRESSION AND TRANSLOCATION IN UNTREATED DLBCL: RESULTS FROM THE PHASE III GOYA STUDY , 2017 .
[4] L. Sehn,et al. The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy. , 2017, European journal of cancer.
[5] R. Gascoyne,et al. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] T. Hishima,et al. Central nervous system relapse in patients with diffuse large B cell lymphoma: analysis of the risk factors and proposal of a new prognostic model , 2016, Annals of Hematology.
[7] R. Gascoyne,et al. Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. , 2016, Blood.
[8] Y. Asmann,et al. Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas , 2015, Clinical Cancer Research.
[9] A. Vignati,et al. Risk‐tailored CNS prophylaxis in a mono‐institutional series of 200 patients with diffuse large B‐cell lymphoma treated in the rituximab era , 2015, British journal of haematology.
[10] K. Yamazaki,et al. Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations , 2015, Leukemia & lymphoma.
[11] Andrew J. Dunford,et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. , 2014, Blood.
[12] W. Wilson,et al. Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma , 2014, Haematologica.
[13] K. Hoang-Xuan,et al. Mutational analysis of primary central nervous system lymphoma , 2014, Oncotarget.
[14] A. Salar,et al. Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome. , 2014, Blood.
[15] Kai Fu,et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. , 2014, Blood.
[16] Alex M. Fichtenholtz,et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.
[17] Steven J. M. Jones,et al. Frequent mutation of histone modifying genes in non-Hodgkin lymphoma , 2011, Nature.
[18] Raul Rabadan,et al. Analysis of the Coding Genome of Diffuse Large B-Cell Lymphoma , 2011, Nature Genetics.
[19] X. Hou,et al. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab , 2011, Annals of Hematology.
[20] Mingming Jia,et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..
[21] T. Molina,et al. Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. , 2010, Blood.
[22] R. Gascoyne,et al. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] Jan Delabie,et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma , 2010, Nature.
[24] N. Schmitz,et al. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). , 2009, Blood.
[25] L. Staudt,et al. Stromal gene signatures in large-B-cell lymphomas. , 2008, The New England journal of medicine.
[26] L. Staudt,et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways , 2008, Proceedings of the National Academy of Sciences.
[27] R. Gascoyne,et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] S. Kvaløy,et al. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[29] Meland,et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[30] B. E. C. Oiffier,et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .
[31] Ulrich Siebenlist,et al. Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells , 2001, The Journal of experimental medicine.
[32] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[33] M. Wolter,et al. Frequent In activation of CDKN2A and Rare Mutation of TP53 in PCNSL , 1998, Brain pathology.
[34] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[35] T. Molina,et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[36] Pierre Morel,et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.